Publications by authors named "Nobuko Nishimura"

Claim this Profile
T
Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe.
Nuria A Tamayo, Matthew P Bourbeau, Jennifer R Allen, Kate S Ashton, Jian Jeffrey Chen, Nobuko Nishimura

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Covalent Inhibitor of KRAS (AMG 510) for the Treatment of Solid Tumors.
Brian A Lanman, Jennifer R Allen, John G Allen, Albert K Amegadzie, Kate S Ashton, Nobuko Nishimura

J Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234].
Longbin Liu, Matthew R Lee, Joseph L Kim, Douglas A Whittington, Howard Bregman, Nobuko Nishimura

Bioorg Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
Longbin Liu, Matthew R Lee, Joseph L Kim, Douglas A Whittington, Howard Bregman, Nobuko Nishimura

Bioorg Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint.
Lewis D Pennington, Michael D Bartberger, Michael D Croghan, Kristin L Andrews, Kate S Ashton, Nobuko Nishimura

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis.
Nuria A Tamayo, Mark H Norman, Michael D Bartberger, Fang-Tsao Hong, Yunxin Bo, Nobuko Nishimura

J Med Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists.
Daniel B Horne, Nuria A Tamayo, Michael D Bartberger, Yunxin Bo, Jeffrey Clarine, Nobuko Nishimura

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine series.
Nobuko Nishimura, Mark H Norman, Longbin Liu, Kevin C Yang, Kate S Ashton

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
David J St Jean, Kate S Ashton, Michael D Bartberger, Jie Chen, Samer Chmait, Nobuko Nishimura

J Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Ryan P Wurz, Longbin Liu, Kevin Yang, Nobuko Nishimura, Yunxin Bo

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
Mark H Norman, Kristin L Andrews, Yunxin Y Bo, Shon K Booker, Sean Caenepeel, Nobuko Nishimura

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Adrian L Smith, Noel D D'Angelo, Yunxin Y Bo, Shon K Booker, Victor J Cee, Nobuko Nishimura

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists.
Nuria A Tamayo, Yunxin Bo, Vijay Gore, Vu Ma, Nobuko Nishimura

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
Nobuko Nishimura, Aaron Siegmund, Longbin Liu, Kevin Yang, Marian C Bryan

J Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Jian Jeffrey Chen, Thomas Nguyen, Derin C D'Amico, Wenyuan Qian, Jason Human, Nobuko Nishimura

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species-specific pharmacology of Trichloro(sulfanyl)ethyl benzamides as transient receptor potential ankyrin 1 (TRPA1) antagonists.
Lana Klionsky, Rami Tamir, Baoxi Gao, Weiya Wang, David C Immke, Nobuko Nishimura

Mol Pain· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Mark H Norman, Jiawang Zhu, Christopher Fotsch, Yunxin Bo, Ning Chen, Nobuko Nishimura

J Med Chem· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Hui-Ling Wang, Jodie Katon, Chenera Balan, Anthony W Bannon, Charles Bernard, Nobuko Nishimura

J Med Chem· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Versatile diastereoselectivity in formal [3,3]-sigmatropic shifts of substituted 1-alkenyl-3-alkylidenecyclobutanols and their silyl ethers.
Michael E Jung, Nobuko Nishimura, Aaron R Novack

J Am Chem Soc· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis